LUCIDI, Paola
 Distribuzione geografica
Continente #
NA - Nord America 2.542
EU - Europa 2.013
AS - Asia 1.572
SA - Sud America 234
AF - Africa 23
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.404
Nazione #
US - Stati Uniti d'America 2.500
SG - Singapore 805
IE - Irlanda 338
UA - Ucraina 305
IT - Italia 276
CN - Cina 265
RU - Federazione Russa 227
SE - Svezia 218
HK - Hong Kong 217
BR - Brasile 206
DE - Germania 175
FI - Finlandia 133
VN - Vietnam 109
FR - Francia 104
GB - Regno Unito 96
KR - Corea 47
TR - Turchia 35
AT - Austria 30
CA - Canada 25
PL - Polonia 25
IN - India 21
AU - Australia 16
JP - Giappone 13
NL - Olanda 13
BE - Belgio 12
CH - Svizzera 11
ES - Italia 11
MX - Messico 11
BD - Bangladesh 9
CZ - Repubblica Ceca 9
AR - Argentina 8
IQ - Iraq 7
RO - Romania 7
ZA - Sudafrica 7
GR - Grecia 6
LB - Libano 6
UZ - Uzbekistan 6
EC - Ecuador 5
VE - Venezuela 5
ID - Indonesia 4
AZ - Azerbaigian 3
EE - Estonia 3
EG - Egitto 3
IL - Israele 3
JO - Giordania 3
KE - Kenya 3
LT - Lituania 3
MA - Marocco 3
NP - Nepal 3
PH - Filippine 3
TW - Taiwan 3
AL - Albania 2
BG - Bulgaria 2
BO - Bolivia 2
BW - Botswana 2
CL - Cile 2
CO - Colombia 2
DK - Danimarca 2
DZ - Algeria 2
EU - Europa 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PS - Palestinian Territory 2
RS - Serbia 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
GE - Georgia 1
HR - Croazia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LV - Lettonia 1
NG - Nigeria 1
PA - Panama 1
PK - Pakistan 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
UY - Uruguay 1
Totale 6.404
Città #
Singapore 530
Chandler 383
Dublin 338
Hong Kong 215
San Mateo 198
Jacksonville 179
Boardman 140
Ashburn 130
Altamura 112
Santa Clara 108
Medford 97
Princeton 96
Wilmington 90
Perugia 80
Ann Arbor 74
Lawrence 74
Beijing 69
Moscow 65
Munich 65
New York 62
Dong Ket 57
Los Angeles 48
Seoul 46
Helsinki 43
Andover 39
Des Moines 27
Saint Petersburg 26
Brooklyn 25
Woodbridge 21
Piscataway 20
Rome 20
Izmir 19
Norwalk 18
São Paulo 18
Warsaw 18
Amelia 17
Chicago 17
Fremont 17
Ho Chi Minh City 17
Vienna 17
Turku 16
Nuremberg 14
Stockholm 13
Tokyo 13
Frankfurt am Main 12
Brussels 11
Denver 11
Falkenstein 10
Falls Church 10
San Paolo di Civitate 10
Ankara 9
Poplar 9
Amsterdam 8
Houston 8
London 8
Milan 8
Montreal 8
Redwood City 8
Belo Horizonte 7
Hanoi 7
Redmond 7
San Diego 7
Atlanta 6
Bexley 6
Chennai 6
Melbourne 6
Renton 6
Shanghai 6
Bolton 5
Brno 5
Bucu 5
Dallas 5
Lausanne 5
Porto Alegre 5
San Francisco 5
Simi Valley 5
The Dalles 5
Athens 4
Auburn Hills 4
Cardiff 4
Columbus 4
Curitiba 4
Haiphong 4
Manchester 4
Mexico City 4
Mumbai 4
Olomouc 4
Orem 4
Toronto 4
Amman 3
Baku 3
Boston 3
Cambridge 3
Campinas 3
Changsha 3
Corridonia 3
Den Haag 3
Durban 3
Guangzhou 3
Istanbul 3
Totale 4.011
Nome #
Hypoglycemia 131
Alternative indicators of metabolic control 120
Liver protein synthesis in physiology and in disease states 119
18. Insulin required for prandial ghrelin suppression in humans 113
Physiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans. 108
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 108
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 105
A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults 105
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 101
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 99
Contribution of amino acids and insulin to protein anabolism during meal absorption. 99
A novel surrogate index for hepatic insulin resistance. 97
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 96
Insulin is required for prandial ghrelin suppression in humans 96
Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients 95
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules. 95
Administration of Recombinant Human GH on Alternate Days is sufficient to increase whole Body Protein Synthesis and Lipolysis in GH Deficient Adults 93
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 91
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 89
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 88
Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study. 86
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules 85
Ethanol impairs post-prandial hepatic protein metabolism 83
Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange 83
SHORT-TERM TREATMENT WITH LOW DOSES OF RECOMBINANT HUMAN GROWTH HORMONE (GH) STIMULATES LIPOLYSIS IN VISCERAL OBESE MEN 82
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 82
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 82
Termoablazione laser percutanea quale alternativa all’intervento di tiroidectomia totale nei pazienti ad alto rischio operatorio 81
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 79
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial 78
Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status 77
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 77
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 76
Effects of dietary protein restriction on albumin and fibrinogen synthesis in macroalbuminuric type 2 diabetic patients. 75
Chloroquine reduces whole body proteolysis in humans 73
Physical inactivity is the main cause of the metabolic syndrome 71
Circulatin ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement 71
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 71
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 71
Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari 71
HYPERGLYCEMIA-INDUCED PLATELET ACTIVATION IN TYPE 2 DIABETES MELLITUS IS RESISTANT TO ASPIRIN BUT NOT TO A NITRIC OXIDE-DONATING AGENT. 70
Dietary protein intake does not affect IgG synthesis in patients with nephrotic syndrome. 69
Body composition and common carotid artery remodeling in a healthy population 69
Circulating ghrelin concentrations in the polycystic ovary syndrome 68
Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. 66
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 66
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 65
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 65
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. 64
Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure 64
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 63
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 63
Circulating ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement. 62
Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. 59
One hour post-load plasma glucose and 3 year risk of worsening fasting and 2 hour glucose tolerance in the RISC cohort 59
Moderate and large doses of ethanol differentially affect hepatic protein metabolism in humans 57
Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients 57
Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. 57
Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. 57
Obesity and carotid artery remodeling 57
Gamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk 57
Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage 55
Low levels of unmodified insulin glargine in plasma of people with type 2 diabetes requiring high doses of basal insulin 55
The effect of menopause on carotid artery remodeling, insulin sensitivity, and plasma adiponectin in healthy women 55
How to accurately establish pharmacokinetics/ pharmacodynamics of long- Acting insulins in humans: Relevance to biosimilar insulins 54
Optimizing the replacement of basal insulin in Type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. 53
Effect of sedentary behaviour and vigorous physical activity on segment-specific carotid wall thickness and its progression in a healthy population 52
Tecniche Nefrologiche e dialitiche 52
Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. 51
Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes. 51
INSULIN SENSITIVITY IN TYPE 2 DIABETIC PATIENTS IS DIFFERENT BETWEEN GLUCOSE AND PROTEIN METABOLISM 50
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations 49
Impact of family history on relations between insulin resistance, LDL cholesterol and carotid IMT in healthy adults 49
Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology 49
Treatment of growth hormone deficiency syndrome in adults 48
Nicotinamide counteracts alcohol-induced impairment of hepatic protein metabolism in humans 48
Gender differences in basal protein kinetics in young adults 47
Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials 47
Plasma ghrelin concentrations, food intake, and anorexia in liver failure 46
Insulin sensitivity and beta-cell function in the offspring of type 2 diabetic patients: impact of line of inheritance. 46
Effects of whole-body vibration exercise on the endocrine system of healthy men. 46
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia 46
From Metabolic Normality to Cardiometabolic Risk Factors in Subjects With Obesity 45
Metabolic effects of an SGLT2 inhibitor (Dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes. Diabetes care 2020;43:2128– 2136 45
Real-time continuous glucose monitoring decreases the risk of severe hypoglycemia in people with type 1 diabetes and impaired awareness of hypoglycemia 44
The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime? 43
Ethanol impairs post-prandial hepatic protein metabolism. 42
Ipoglicemia: implicazioni cliniche e impatto sulla salute 42
The physiological basis of insulin therapy in people with diabetes mellitus 42
Plasma Insulin Levels and Hypoglycemia Affect Subcutaneous Interstitial Glucose Concentration 40
Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by Type 2 diabetic subjects. 40
Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans 39
Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population 36
GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: Lessons from the 4B and Get-Goal DUO 2 trials 36
Reductions in A1C with pump therapy in type 2 diabetes are independent of C-peptide and anti-glutamic acid decarboxylase antibody concentrations 36
One-hundred year evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs 34
Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. 33
Glucose Control in Diabetes: Targets and Therapy 29
Totale 6.591
Categoria #
all - tutte 33.266
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.266


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021359 0 0 0 0 0 55 53 17 78 24 60 72
2021/2022706 12 137 21 38 18 9 8 231 7 18 99 108
2022/20231.259 99 264 17 89 92 158 0 58 445 1 28 8
2023/2024519 35 49 28 7 2 11 100 0 54 26 103 104
2024/20251.320 10 124 31 79 203 43 38 108 292 93 169 130
2025/20261.325 219 184 157 271 413 81 0 0 0 0 0 0
Totale 6.591